What is the study about?
TargetTau is a clinical trial looking at whether a new drug can slow the progression of Alzheimer’s disease. Our Trust is the first centre in England to offer an opportunity to take part in this trial, which is sponsored by the biopharmaceutical company Bristol Myers Squibb. Spaces for participants are very limited.
What is involved?
The study includes an 8-week screening period followed by a 76-week double-blind treatment phase, during which participants will receive either the active drug, BMS-986446, or a placebo. At the end of the Phase II trial, all participants may have the opportunity to join an extended study where everyone receives the new drug.
Who can take part?
We are looking for participants aged 50-80 years who have a diagnosis of mild cognitive impairment or early Alzheimer’s disease. Participants must also weigh 70kg-120kg.